InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: NY1972 post# 153

Tuesday, 08/30/2022 2:29:53 PM

Tuesday, August 30, 2022 2:29:53 PM

Post# of 386
It turns out that the FDA's concerns about BEAM's BEAM-201 are multi-faceted, with the agency requesting ''additional control data from genomic rearrangement assessments'' and ''further analyses of certain off-target editing experiments.'' In addition, the agency is also looking for more control data for a ''cytokine-independent growth assay'' and ''updated investigator brochure that includes information regarding any new nonclinical studies.'' The company has guided to a response submission in Q4.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News